According to a single-center study, Molnupiravir showed good tolerability and was related to favorable COVID-19 outcomes. In order to determine if the patient profile and short-term COVID-19 results are similar to those of clinical trial subjects from the pivotal MOVe-OUT study, Anca Streinu-Cercel et al. analyzed data concerning the real-world therapeutic usage of Molnupiravir.

Complete clinical data were available for 46 outpatients who were given Molnupiravir treatment; 56.5% (n = 20) of these patients were men with median age of 48.5 years (Interquartile range [IQR]: 37.8, 67.0 years). The percentage of subjects with a minimum 1 chronic disease was 54.2% (n = 26). Notably, 28.9% (13 out of 45) individuals who had their lungs examined using lung computed tomography imaging had alterations indicative of SARS-CoV-2 pneumonia.

Presence of SARS-CoV-2 vaccine was highly protective against pneumonia. All individuals had symptoms, and Molnupiravir was started 3.5 (±1.5) days on average after the onset of symptoms. All subjects, with the exception of 1, confirmed a favorable course under intervention, with severity of SARS-Co-2 infection not getting worse, and betterment in symptoms; none of them needed hospitalization or advanced to respiratory failure.

This was done 5 days after the initial assessment and the start of Molnupiravir intervention. In routine practice, Molnupiravir therapy was well-tolerated and linked to positive COVID-19 results in a clinical population that was somewhat older, had fewer comorbidities, and had a greater incidence of COVID-19 immunization than that from the pivotal study.